Biogen Q1 profits rise boosted by Tecfidera sales
April 22, 2016Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera
Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
Novartis muscular drug fails in Phase III trials
April 22, 2016Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
Actelion ups outlook for 2016, reports Q1 net income up 12%
April 22, 2016Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook
Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …
A win for Sanofi on Jevtana after NICE reverses guidance
April 22, 2016Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal
Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference
April 21, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation
Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …
Shares plunge at Sarepta after negative FDA review on muscle disorder drug
April 21, 2016Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta
Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …
GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA
April 21, 2016Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy
GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …
Novartis drug Afinitor significantly reduces seizures in TSC patients
April 21, 2016Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc
Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …
BioMarin announces positive data from early stage trials of haemophilia A gene therapy
April 21, 2016Research and Development BioMarin Pharmaceutical, Phase II, drug trial, haemophilia A gene therapy
BioMarin Pharmaceutical (Nasdaq: BMRN) said early-stage trials for its haemophilia A gene therapy showed encouraging data. Chief Medical Officer, Hank …
Amgen’s drug reduces rates of bleeding in rare childhood disorder
April 21, 2016Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim
Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
Novartis Q1 earnings drop as cancer drug sales falter
April 21, 2016Business Services, Sales and Marketing Financial, Novartis, earnings, first quarter, results
Swiss drugmaker Novartis (SIX: NOVN) on Thursday reported a 13% drop in net income for the first quarter on the …
Abbvie acquires immune-oncology target from argenx
April 21, 2016Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive
AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …
Illumina shares plunge as it cuts Q1 outlook
April 20, 2016Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market
Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …
Focus: Bristol-Myers Squibb’s wonder drug – Opdivo
April 20, 2016Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales
By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure
April 20, 2016Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly
Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …
Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business
April 20, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results
Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …
Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies
April 20, 2016Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir
Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
J&J raises FY outlook, Q1 beats estimates
April 20, 2016Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales
Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …
Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data
April 20, 2016Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme
Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
